Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Bad Nenndorf – page 39

792 clinical trials in Bad Nenndorf, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Bad Nenndorf at a glance
792
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

792 trials in Bad Nenndorf

Open in trial search

Adenocarcinoma gastric+3

Not recruiting

Study of zolbetuximab, pembrolizumab and chemotherapy in adults with HER2-negative, Claudin 18.

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Astellas Pharma Global Development Inc.

Chronic hepatitis C

Not recruiting

Comparing bemnifosbuvir-ruzasvir and sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in adult patients

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bemnifosbuvir
  • Sponsor:Atea Pharmaceuticals Inc.

Study of BI 765423 given by intravenous infusion for patients with idiopathic pulmonary fibrosis with or without standard treatment

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BI 765423
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study of vicadrostat and empagliflozin given together or separately in people with chronic kidney disease to test safety and effectiveness

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim Espana S.A.

Hidradenitis

Not recruiting

Study of ruxolitinib cream applied to the skin for people with hidradenitis suppurativa

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Ruxolitinib
  • Sponsor:Incyte Corp.

Study of ABBV-CLS-628 to evaluate safety and effectiveness in adults with Autosomal Dominant Polycystic Kidney Disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:ABBV-CLS-628
  • Sponsor:Calico Life Sciences LLC

Hepatitis D

Not recruiting

Clinical Trial for Patients with Chronic Hepatitis D: Comparing Brelovitug and Bulevirtide Treatments

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BJT-778
  • Sponsor:Mirum Pharmaceuticals Inc.

Study on the Effectiveness and Safety of EYE103 Compared to Ranibizumab for Patients with Diabetic Macular Edema

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:EYE103
  • Sponsor:Eyebiotech Limited

Influenza

Not recruiting

Study on the Safety and Immune Response of aQIVc HD Vaccine Compared to a Drug Combination for Adults 50 Years and Older at Risk of Flu Complications

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:A/(H3N2)-LIKE VIRUS ANTIGEN
  • Sponsor:Seqirus UK Limited

Study on the Effectiveness of Durvalumab and BCG in Treating High-Risk, Non-Muscle Invasive Bladder Cancer in Patients New to BCG Treatment

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Coronavirus infection

Not recruiting

Study on COVID-19 Prevention Using Sipavibart and Cilgavimab for Patients with Weakened Immune Systems

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years · Healthy volunteers
  • Substances:Cilgavimab
  • Sponsor:AstraZeneca AB
Countries:GermanyGermany
  • Participants:0–17 years · Healthy volunteers
  • Substances:Clesrovimab
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Bad Nenndorf

What the registry says about research in the country

01 Cardiovascular Diseases

Researchers in Bad Nenndorf are evaluating how a novel oral agent elecoglipron influences the progression of chronic kidney disease in adult participants, with all patients receiving background therapy with the SGLT2i dapagliflozin. The studies aim to reduce the risk of a sustained ≥50% decline in kidney function, end‑stage kidney disease, or death.

  • Renal outcomes linked to cardiovascular risk
  • Impact of SGLT2 inhibitor background therapy
  • Monitoring of eGFR decline and albuminuria levels
  • Composite endpoint of kidney failure and all‑cause mortality

Both trials are actively recruiting at two local sites, offering patients the opportunity to contribute to advancing therapies that bridge heart and kidney health.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.